Nektar Therapeutics
NASDAQ: NKTR0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Howard W. Robin
- Employees
- 61
- Headquarters
- San Francisco, United States
- IPO year
- 1994
- Market cap
- $1.3B
- Website
- https://www.nektar.com
Loading NKTR…
Loading profile data…Frequently asked questions about NKTR
What does Nektar Therapeutics (NKTR) do?
Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma...
Where does NKTR trade?
Nektar Therapeutics (NKTR) trades on the NASDAQ Global Select.
What sector is NKTR in?
Nektar Therapeutics (NKTR) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Nektar Therapeutics?
Howard W. Robin is the chief executive officer of Nektar Therapeutics (NKTR).
Where is Nektar Therapeutics headquartered?
Nektar Therapeutics is headquartered in United States.
Does NKTR pay a dividend?
Nektar Therapeutics (NKTR) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did NKTR go public?
Nektar Therapeutics (NKTR) completed its initial public offering in 1994.